131 related articles for article (PubMed ID: 38509800)
1. Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity.
Franco S; Khan T; Dinner S; Karmali R; Melody M
J Oncol Pharm Pract; 2024 Jul; 30(5):945-949. PubMed ID: 38509800
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
Wenzell CM; Gallagher EM; Earl M; Yeh JY; Kusick KN; Advani AS; Kalaycio ME; Mukherjee S; Tiu RV; Maciejewski JP; Sekeres MA
Am J Hematol; 2013 Oct; 88(10):906-9. PubMed ID: 23828018
[TBL] [Abstract][Full Text] [Related]
3. Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.
Bray WM; Bivona C; Rockey M; Henry D; Grauer D; Abhyankar S; Aljitawi O; Ganguly S; McGuirk J; Singh A; Lin TL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):691-7. PubMed ID: 26231954
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
6. Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
Foran JM; Sun Z; Lai C; Fernandez HF; Cripe LD; Ketterling RP; Racevskis J; Luger SM; Paietta E; Lazarus HM; Zhang Y; Bennett JM; Levine RL; Rowe JM; Litzow MR; Tallman MS
Cancer; 2023 Aug; 129(16):2479-2490. PubMed ID: 37185873
[TBL] [Abstract][Full Text] [Related]
7. [The Relationship between Body Mass Index and Adult Acute Myeloid Leukemia].
Wang YN; Wei T; Xi YM; Yang MY; Niu L; Wang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):677-684. PubMed ID: 34105456
[TBL] [Abstract][Full Text] [Related]
8. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
[TBL] [Abstract][Full Text] [Related]
10. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
12. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
[TBL] [Abstract][Full Text] [Related]
13. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
Wang ES; Goldberg AD; Tallman M; Walter RB; Karanes C; Sandhu K; Vigil CE; Collins R; Jain V; Stone RM
J Clin Oncol; 2024 May; 42(15):1776-1787. PubMed ID: 38324741
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
[TBL] [Abstract][Full Text] [Related]
15. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
[TBL] [Abstract][Full Text] [Related]
16. Health state utilities associated with treatment options for acute myeloid leukemia (AML).
Matza LS; Deger KA; Howell TA; Koetter K; Yeager AM; Hogge D; Fisher V; Louie AC; Chung KC
J Med Econ; 2019 Jun; 22(6):567-576. PubMed ID: 30775943
[No Abstract] [Full Text] [Related]
17. Anthracycline dose intensification in acute myeloid leukemia.
Fernandez HF; Sun Z; Yao X; Litzow MR; Luger SM; Paietta EM; Racevskis J; Dewald GW; Ketterling RP; Bennett JM; Rowe JM; Lazarus HM; Tallman MS
N Engl J Med; 2009 Sep; 361(13):1249-59. PubMed ID: 19776406
[TBL] [Abstract][Full Text] [Related]
18. Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.
Krashin E; Dolberg OJ; Hellmann I; Huitema AD; Rosing H; Ellis M
Anticancer Drugs; 2016 Sep; 27(8):800-3. PubMed ID: 27254285
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy options for previously untreated acute myeloid leukemia.
Lynch RC; Medeiros BC
Expert Opin Pharmacother; 2015; 16(14):2149-62. PubMed ID: 26364895
[TBL] [Abstract][Full Text] [Related]
20. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF; Link E; Di Iulio J; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D'Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF;
J Clin Oncol; 2017 May; 35(15):1678-1685. PubMed ID: 28368672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
